| Overcoming endocrine resistance in breast cancer AB Hanker, DR Sudhan, CL Arteaga Cancer cell 37 (4), 496-513, 2020 | 748 | 2020 |
| Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer L Formisano, Y Lu, A Servetto, AB Hanker, VM Jansen, JA Bauer, ... Nature communications 10 (1), 1373, 2019 | 349 | 2019 |
| Cathepsin L targeting in cancer treatment DR Sudhan, DW Siemann Pharmacology & therapeutics 155, 105-116, 2015 | 208 | 2015 |
| Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer S Croessmann, L Formisano, LN Kinch, PI Gonzalez-Ericsson, ... Clinical Cancer Research 25 (1), 277-289, 2019 | 123 | 2019 |
| Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells DR Sudhan, DW Siemann Clinical & experimental metastasis 30 (7), 891-902, 2013 | 86 | 2013 |
| Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity AB Hanker, BP Brown, J Meiler, A Marín, HS Jayanthan, D Ye, CC Lin, ... Cancer cell 39 (8), 1099-1114. e8, 2021 | 73 | 2021 |
| Therapeutic potential of adipose stem cell‐derived conditioned medium against pulmonary hypertension and lung fibrosis A Rathinasabapathy, E Bruce, A Espejo, A Horowitz, DR Sudhan, A Nair, ... British Journal of Pharmacology 173 (19), 2859-2879, 2016 | 61 | 2016 |
| Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94 DR Sudhan, MB Rabaglino, CE Wood, DW Siemann Clinical & experimental metastasis 33, 461-473, 2016 | 56 | 2016 |
| Hyperactivation of TORC1 drives resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers DR Sudhan, A Guerrero-Zotano, H Won, PG Ericsson, A Servetto, ... Cancer cell 37 (2), 183-199. e5, 2020 | 54 | 2020 |
| Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer A Servetto, R Kollipara, L Formisano, CC Lin, KM Lee, DR Sudhan, ... Clinical Cancer Research 27 (15), 4379-4396, 2021 | 50 | 2021 |
| Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model DR Sudhan, C Pampo, L Rice, DW Siemann International journal of cancer 138 (11), 2665-2677, 2016 | 48 | 2016 |
| Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer K Lee, AL Guerrero-Zotano, A Servetto, DR Sudhan, CC Lin, L Formisano, ... Nature communications 11 (1), 5488, 2020 | 45 | 2020 |
| Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers … DR Sudhan, LJ Schwarz, A Guerrero-Zotano, L Formisano, MJ Nixon, ... Clinical Cancer Research 25 (2), 771-783, 2019 | 44 | 2019 |
| Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L EN Parker, J Song, GDK Kumar, SO Odutola, GE Chavarria, ... Bioorganic & medicinal chemistry 23 (21), 6974-6992, 2015 | 41 | 2015 |
| Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast cancer K Lee, CC Lin, A Servetto, J Bae, V Kandagatla, D Ye, GM Kim, ... Cancer immunology research 10 (7), 829-843, 2022 | 30 | 2022 |
| Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer A Marín, AA Mamun, H Patel, H Akamatsu, D Ye, DR Sudhan, L Eli, ... Cancer research 83 (18), 3145-3158, 2023 | 11 | 2023 |
| Neratinib: Inching Up on the Cure Rate of HER2+ Breast Cancer? N Unni, DR Sudhan, CL Arteaga Clinical Cancer Research 24 (15), 3483-3485, 2018 | 11 | 2018 |
| Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion R Kudo, A Safonov, C Jones, E Moiso, JR Dry, H Shao, S Nag, ... Cancer cell 42 (11), 1919-1935. e9, 2024 | 10 | 2024 |
| Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer L Formisano, Y Lu, VM Jansen, JA Bauer, A Hanker, P Gonzalez Ericsson, ... Cancer Research 78 (4_Supplement), GS6-05-GS6-05, 2018 | 9 | 2018 |
| Abstract P3-07-13: The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor α C Morrow, L Carnevalli, RD Baird, T Brier, C Ciardullo, N Cureton, ... American Association for Cancer Research (AACR), 2023 | 2 | 2023 |
